6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Oorspronkelijke tekst

Deze vertaling beoordelen

Je feedback wordt gebruikt om Google Translate te verbeteren

Latest Press Releases

Time	Headline
43m ago	NVIDIA Founder, CEO Jensen Huang to Carnegie Mellon University Graduates: 'Shape What Comes Next'
43m ago	RadNet Reports Record First Quarter Financial Results and Revises Upwards 2026 Imaging Center Financial Guidance Ranges for Revenue, Adjusted EBITDA and Free Cash Flow
1h ago	Faraday Future Acknowledged and Appointed YT Jia as Sole Global CEO and Jerry Wang Appointed Global Executive Chairman; FF to Announce Upgraded Transformation Initiatives Next Week to Begin a New Growth Chapter as a Physical AI Company
22h ago	Club Offers for Travel Enthusiasts in Germany
23h ago	Montfort Capital Announces Delay in Filing Annual Financial Statements and MD&A, Issuance of Cease Trade Order

About

Ovid Therapeutics Inc. — investor relations, events, news, and company updates on 6ix.

Latest News

Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14

Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results

Ovid Therapeutics Announces Pricing of $60 Million Private Placement

Ovid Therapeutics to Participate in Upcoming Investor Conferences

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

Recent Videos

RANGE BREAKOUT | OVID STOCK ANALYSIS | OVID THERAPEUTICS STOCK

RANGE BREAKOUT | OVID STOCK ANALYSIS | OVID THERAPEUTICS STOCK

May 08, 2026

Ovid Therapeutics' Dr. Jeremy M. Levin shares details from his new book: "Biotech in the Balance"

Ovid Therapeutics' Dr. Jeremy M. Levin shares details from his new book: "Biotech in the Balance"

May 04, 2026

Ovid Therapeutics Raises $53.9M: Shareholder Concerns?

Ovid Therapeutics Raises $53.9M: Shareholder Concerns?

Apr 20, 2026

OVID STOCK : STRONG RECOVERY | OVID THERAPEUTICS STOCK

OVID STOCK : STRONG RECOVERY | OVID THERAPEUTICS STOCK

Apr 19, 2026

Community Chat

Ask AI